Research and Innovation

NIHR GOSH BRC spinout Orchard Therapeutics signs strategic agreement with GSK

GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients.

UK-wide consortium to transform treatment for children and young people with arthritis and uveitis

Researchers from the UCL Great Ormond Street Institute of Child Health (ICH) and Great Ormond Street Hospital (GOSH) will lead a UK-wide effort to drive the development of new, targeted treatments for children and young people with juvenile idiopathic arthritis (JIA) and its associated eye-inflammation condition, uveitis.

New tablet reduces symptoms for young people with multiple sclerosis

A daily tablet has been shown to reduce the debilitating symptoms experienced by children with Multiple Sclerosis (MS) and cut the chance of relapse by 82%. There are currently no treatments specifically approved for adolescents with MS and this is the first time that an MS drug has been trialled specifically in young people.

​New genetic test leads to faster, more accurate diagnosis of childhood eye disorders

A new test to help diagnose and predict a range of serious childhood eye conditions has been developed by researchers at Great Ormond Street Hospital (GOSH) and the UCL Great Ormond Street Institute of Child Health (ICH).

Advances in the treatment of the severe immune disorder Wiskott-Aldrich syndrome

Researchers at Great Ormond Street Hospital (GOSH) have made an important breakthrough in understanding how the immune system becomes disrupted in Wiskott-Aldrich syndrome (WAS), a genetic disorder where the patient’s immune cells begin attacking their own body.